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Abstract
Bcl-2 is an anti-apoptotic protein that is frequently overex-pressed in cancer cells but its role in
carcinogenesis is not clear. We are interested in how Bcl-2 expression affects non-cancerous breast
cells and its role in the cell cycle. We prepared an MCF10A breast epithelial cell line that stably
overexpressed Bcl-2. We analyzed the cells by flow cytometry after synchronization, and used cDNA
microarrays with quantitative reverse-transcription PCR (qRTPCR) to determine differences in gene
expression. The microarray data was subjected to two pathway analysis tools, parametric analysis of
gene set enrichment (PAGE) and ingenuity pathway analysis (IPA), and western analysis was carried
out to determine the correlation between mRNA and protein levels. The MCF10A/Bcl-2 cells
exhibited a slow-growth phenotype compared to control MCF10A/Neo cells that we attributed to a
slowing of the G1-S cell cycle transition. A total of 363 genes were differentially expressed by at
least two-fold, 307 upregulated and 56 downregulated. PAGE identified 22 significantly changed
gene sets. The highest ranked network of genes identified by IPA contained 24 genes. Genes that
were chosen for further analysis were confirmed by qRT-PCR, however, the western analysis did
not always confirm differential expression of the proteins. Downregulation of the phosphatase
CDC25A could solely be responsible for the slow growth pheno-type in MCF10A/Bcl-2 cells.
Increased levels of GTPase Cdc42 could be adding to this effect. PAGE and IPA are valuable tools
for microarray analysis, but protein expression results do not always follow mRNA expression
results.
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Introduction
The B-cell lymphoma gene (Bcl-2) is a negative regulator of apoptosis, and its overexpression
has been found in a large number of cancers.1 Bcl-2 has been hypothesized to play two separate
roles in the development and progression of cancer. First, the inhibition of apoptosis by Bcl-2
may allow cells to persist until other oncogenes such as c-MYC are activated.2 In addition,
Bcl-2 is a potent suppressor of apoptosis induced by most stress applications, including
chemotherapeutic drugs.3 Most anti-cancer agents are designed to induce apoptosis, yet
overexpression of Bcl-2 increases drug resistance in cancer cells. Interestingly, although
Bcl-2 is over-expressed in breast cancer, its expression is associated with a positive prognosis.
4 This fact may be a result of Bcl-2′s negative effect on cell cycle progression.5,6 It is this
seemingly paradoxical effect of Bcl-2 that we chose to examine.
There are multiple ways in which apoptosis and cell cycle regulation pathways cross.6 Bcl-2
slows cell proliferation by lengthening the cell cycle.7,8 Expression of Bcl-2 increases the
amount of time cells spend in G1, thereby slowing the G1-S transition.9-12 The exact
mechanism of this effect is unknown, however, some cell lines displayed a downregulation of
cell cycle inhibitor p21WAF1/CIP1,13 upregulation of inhibitor p27KIP1,12,14
hypophosphorylated retinoblastoma protein (pRb)15 and reduced active levels of transcription
factor E2F.14
We are interested in determining what gene expression changes occur upon Bcl-2
overexpression in MCF10A cells. In this paper, we focus on gene expression changes in cell
cycle and cell proliferation genes. Our long-term goal is to shed light on gene expression
patterns leading to breast cancer development. Previous studies have demonstrated that
Bcl-2 expression in MCF10A cells causes an altered cell cycle,10 but this is the first time
microarray analysis has been reported.
Since MCF10A cells were immortalized spontaneously from mortal diploid cells, the cell line
exhibits characteristics of normal breast epithelium: (a) three-dimensional growth in collagen;
(b) control of growth in culture by hormones and growth factors; (c) lack of anchorage-
independent growth; (d) dome formation in confluent cultures; and (e) lack of tumorigenicity
in nude mice.16 Several studies have used the MCF10A cell line as a control in breast cancer
cell studies, and therefore we hypothesized that MCF10A could substitute for non-transformed
cells in culture.17,18 In fact, the cell line has been the focus of a study to examine cytogenetic
changes that occur upon breast cancer progression.19
We prepared a stable Bcl-2-expressing MCF10A cell line (MCF10A/Bcl-2) by retroviral
infection, and showed that MCF10A/Bcl-2 cells had a significantly lower growth rate
compared to control MCF10A/Neo cells caused by a slowing of the G1-S transition of the cell
cycle. Subsequently, a cDNA microarray analysis comparing the two cell lines was performed
and the data subjected to two separate pathway analysis tools. We hypothesized that BCL2
overexpression would downregulate genes involved in the G1-S phase transition, and genes
that block cell cycle progression would be upregulated. PAGE identified 22 significantly
changed gene sets, and the highest ranked network identified by IPA contained 24 significant
genes. By qRT-PCR we confirmed the upregulation of two cell cycle genes, CCND1 and
CDC42 and the downregulation of the cell cycle phosphatase gene CDC25A. However, western
analysis did not confirm the upregulation of cyclin D1 protein. In addition, genes for several
transcriptional activators of CCND1 such as FN1 and TGFβ3 were also shown to be
differentially regulated. Therefore, we demonstrate that BCL2 overexpression causes
phenotypic changes that can be correlated to specific gene expression changes with microarray
and pathway analysis, but protein analysis is necessary to confirm their involvement.
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Results
Bcl-2 expression and the cell cycle
To verify the successful introduction of our BCL2 construct, western blot analysis with
antibodies to Bcl-2 was performed to determine expression level of the introduced Bcl-2 protein
in the MCF-10/Bcl-2 cell line. The MCF10A/Bcl-2 cells expressed Bcl-2, while there was no
detectable expression in the parent MCF10A and the MCF10A/Neo cells under the same
conditions while the expression of β-actin, which was used as a loading control, was equivalent
in all three cell lines (Fig. 1). However, a longer exposure with a higher antibody concentration
did result in a positive Bcl-2 signal in MCF10A and MCF10A/Neo cells (data not shown).
These results confirm that the BCL2 construct was successfully introduced and expressed at a
high level in the MCF10A/Bcl-2 cell line.
Cell counts were performed by trypan blue exclusion to determine the growth rate for each of
our cell lines (Fig. 2). MCF10A (circle) and MCF10A/Neo cells (square) showed similar
growth rates with a doubling time of approximately 50 h. MCF10A/Bcl-2 cells (triangle) were
observed to have a significantly slower growth rate with a doubling time of approximately 90
h.
We endeavored to determine which stage of the cell cycle was altered in the MCF10A/Bcl-2
cells. We synchronized cells by two different methods. First, cells were grown without growth
factors (GF) for five days, and then GF were added. Growth factor addition after
synchronization causes cells to enter S phase. Flow cytometry with PI was used to determine
the percentage of cells at each phase of the cell cycle. Figure 3A is a graph of the number of
MCF10A/Neo cells in each phase as determined by ModFit analysis of flow cytometry data,
starting on the day GF were added. Each bar represents counts from an average of three
independent experiments carried out in duplicate. Approximately 80% of MCF10A/Neo cells
were in G1 at time 0, after five days GF withdrawal. By 21 h 60% of the cells had left G1 and
were in S or G2 phase.
Figure 3B is a graph of the same cell cycle analysis done with MCF10A/Bcl-2 cells after GF
re-addition. Many cells were floating in the medium during the five days of GF withdrawal
but only live (adherent) cells were used for analysis. Ninety percent of MCF10A/Bcl-2 cells
were in G1 five days after GF withdrawal (time zero). In contrast to the MCF10A/Neo cells,
the MCF10A/Bcl-2 cells remained in G1 longer, up to 24 h after GF re-addition. T-tests
confirmed that from 18–24 h, the MCF10A/Bcl-2 cell line had a significantly higher number
of cells in G1 vs the MCF10A/Neo cell line. The cells progressed from S phase to G2 phase
during the 24 to 36 h period. However, there seemed to be fewer cells in S and G2 phases in
the MCF10A/Bcl-2 cell line overall compared to the control. Bcl-2 has been implicated in cell
cycle exit to G0, as well as inducing a slow G1-S transition.20 Therefore, it appears that the
MCF10A/Bcl-2 cells were slow to leave G1 and enter S and G2 phase compared to the control
cell line, and some cells may have exited into G0 instead of continuing to cycle.
Cells were also synchronized with the microtubule inhibitor colchicine. Colchicine inhibits
microtubule proliferation and arrests cells in the G2 phase.21 Cells were treated with 0.1 μM
colchicine and stained with PI. The control was untreated cells that were harvested at 70%
confluency. Figure 3C is a graph of the cell cycle distribution of MCF10A/Neo cells treated
with colchicine. Each bar represents cell counts from three independent experiments carried
out in duplicate. Control cells (time 0) were 80% in G1 at time 0. Colchicine-treated cells began
to leave G1 on day one of treatment. Approximately 60% of MCF10A/Neo cells were in G2
on day two of treatment and 80% of the cells were in G2 by day four. On day five the MCF10A/
Neo cells started to die, indicated by the sub-G1 peak (referred to as dead on graph), and there
was an increase in death on day four and day five.
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Figure 3D is a graph representing the cell cycle distribution of MCF10A/Bcl-2 cells when
treated with colchicine. The control was untreated MCF10A/Bcl-2 cells that were harvested at
70% confluency. Control cells (time 0) were 70% in G1 at time 0. On day two of treatment, t-
tests confirmed that there were significantly more cells in G1 and significantly fewer cells in
S and G2 compared to the same time point in MCF10A/Neo cells (Fig. 3C). Therefore, as with
GF withdrawal synchronization, the MCF10A/Bcl-2 cells were slower to leave G1 than the
MCF10A/Neo cells. MCF10A/Bcl-2 cells started dying (as indicated by the sub-G1 peak) on
day three, and there were significantly more dead cells at days three, four and five compared
to the same time points of MCF10A/Neo cells. Day four shows 60% of the total events collected
(10,000) were sub-G1, indicating that the cells were dead. Day five had 40% of total events as
sub-G1. This number was lower than day four’s total because there was more cellular debris
that was not counted as sub-G1 in the latter. Subsequent analysis showed that this death was
apoptotic (data not shown).
Microarray analysis
In order to identify differentially expressed genes, the gene expression profiles of the two cell
lines, MCF10A/Neo and MCF10A/Bcl-2, were compared. The raw intensity values from the
Phosphoroimager 860 were normalized to allow comparison of values from different arrays
using a Z score normalization method.22 This method ultimately produced a distribution of Z
scores for all the genes in each array, and used the differences in the Z scores to calculate Z
ratios to locate genes that were expressed differentially.22,23 Genes that had a Z ratio >1.5
and a p-value <0.05 were considered significant. This narrowed the number of significant genes
to 363, including 307 upregulated and 56 downregulated. The data was then analyzed using
two functional analysis tools.
Parametric analysis of gene set enrichment (PAGE) uses the fold change between the control
and experimental groups to calculate Z scores of predefined gene sets and normal distribution
to assign statistical significance to the gene sets.24 The list of all of the genes used in the array
and their Z scores are put into the analysis and Z scores are assigned to the functional groups
within each cell line. A list of genes involved in each pathway and their individual Z scores
are also displayed in the analysis. Traditional microarray data analysis requires that individual
genes have significantly different expression levels in order for them to be considered
differentially regulated. PAGE takes into account that genes are co-regulated. Therefore, it is
possible that genes individually may not be significant, but significant differences can be
demonstrated by grouping genes into gene sets. By looking at groups of genes involved in a
specific function, significant differences represent a biologically meaningful result.
The PAGE graph shows Z scores of every significantly changed pathway between the
MCF10A/Bcl-2 and MCF10A/Neo cell lines (Fig. 4A). The Z scores for each of these pathways
were significantly different because, in most cases, the Z score for the pathway in the other
cell line was zero. These pathways included insulin signaling, gross chromosomal
rearrangements, DNA repair, and others involved in apoptosis and blocking cell cycle
progression.25 When we looked at the pathways for processes such as glycolysis or
gluconeogenesis, common pathways in every cell, we saw no significant difference in the Z
scores. In addition, we observed that despite the fact the MCF10A/Bcl-2 cells spent more time
in G1 than the MCF10A/Neo cells, there was no significant difference in the Z score for cell
cycle arrest pathway.
Ingenuity Pathway Analysis (IPA) assigns biological functions to genes using the Ingenuity
Pathways Knowledge Base (Ingenuity Systems, Inc., Redwood City, CA). The knowledge base
comprises over 200,000 full text articles and information about thousands of human, mouse,
and rat genes.26 This information is used to form networks to create an ‘interactome’ of genes
all involved in specific biological processes. IPA groups significant genes according to the
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biological processes in which they function. The program displays the genes’ significance
values, the other genes with which it interacts, and how the genes’ products directly or indirectly
act on each other, including those not involved in the microarray analysis.26,27 The networks
created are ranked depending on the number of significantly expressed genes they contain. The
highest ranked network identified by IPA contained 24 significant genes (Fig. 5). This network
includes genes whose products function in controlling the cell cycle, cell proliferation,
metastasis, and angiogenesis.
From this network, eight genes, AGT, AKR1C3, CDC25A, CYR6, FN1, MMP1, TGFβ3 and
TGFβI, were selected for further analysis, in addition to CDC42 and CCND1 (Fig. 5B) (Table
1). We chose genes that were limited to those significantly expressed genes and their
transcription factors that are necessary for cell proliferation and cell cycle progression. These
genes were then located in the PAGE analysis to determine how the two analysis tools
compared (Fig. 4B). Three of the target genes identified in the network analysis by IPA were
not found in the PAGE analysis results: AKR1C3, TGFβI and MMP1. However, the other six
genes and BAX were found in ten different pathways. CDC42, CDC25A and CCND1 were all
found in the glutamate downregulation pathway (Glut Down), while only CDC42 and
CDC25A were found in the rapamycin downregulation pathway (Rap Down). CDC25A was
also found in the pathway that involves the activation of Src by protein-tyrosine phosphatase
alpha (srcRPTP Pathway). All of the other target genes showed no pathways in common.
TGFβ3 alone was found in the estrogen receptor modulators downregulated signature gene set
(Frasor ER Down). CYR61 was in the GNF female genes set, while FN1 was found in the G13
signaling pathway and the hematopoesis related transcription factor gene set (Hemo-TF-List-
JP). BAX was found in a total of three gene sets, including the Bcl-2 family and regulatory
network, the mitochondria apoptotic pathway, and the radiation sensitivity gene set. AGT was
not pursued as it could not be confirmed by qRT-PCR (see below).
qRT-PCR analysis
Quantitative reverse transcription PCR (qRT-PCR) was performed with primers specific for
each target gene to verify changes in gene expression between the MCF10/Neo and the MCF10/
Bcl-2 cell lines. The fold-change values for each target gene are shown in Table 1. Genes that
were overexpressed according the microarray showed a 3–11 fold increase in expression in the
MCF10A/Bcl-2 cell line by qRT-PCR (Fig. 6). In addition, Bcl-2 was overexpressed
approximately 800-fold (data not shown). Genes that were under-expressed showed a 0.29–
0.59 fold decrease in expression in the MCF10A/Bcl-2 cell line (Fig. 6). One gene, AGT, from
the network shown in Figure 5B could not be amplified by qRT-PCR even though two sets of
primers were attempted.
Western analysis
We carried out western analysis of several proteins with commercially-available antibodies
(Fig. 7). Several antibodies did not show any bands (data not shown). We attribute this result
to a low expression level of these proteins, or lack of specificity of the antibody. Bax, Cdc42,
and Fn1 were slightly overexpressed in MCF10A/Bcl-2 cells. Cyclin D1 did not show
overexpression in MCF10A/Bcl-2 cells, although the mRNA was overexpressed 8-fold by
qRT-PCR (Table 1).
Discussion
In general, studies that have examined Bcl-2′s cell cycle effects have hypothesized that Bcl-2
affects the kinetics of cell cycle progression at the G1-S transition.9-12 Specifically, Lin et al.,
showed that Bcl-2 slows the cell cycle and increases cyclin D1 expression, and used reporter
plasmids to show that Bcl-2 induces cyclin D1 promoter activity.10 Our study has followed
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up on these findings with microarray analysis to arrive at a possible gene expression pattern
that accounts for the phenotypic changes that occur upon Bcl-2 overexpression. Like their cell
line, ours exhibited significantly slower proliferation compared to the control MCF10A/Neo
cells, and we showed they were slowed in the transition between the G1 and S phases.
A cDNA microarray comparing the MCF10A/Neo and the MCF10A/Bcl-2 cell lines produced
363 significantly changed genes. In order to determine which genes were of interest in the
understanding of the altered cell cycle phenotype, we analyzed the Z score and Z ratio data
with two pathway analysis tools. PAGE showed that several pathways were up or
downregulated equally in both cell lines. This result could be due to the growth conditions for
the cells, since they are grown in the presence of factors such as epidermal growth factor,
insulin and cholera toxin. There were 22 gene sets that were differentially regulated between
the two cell lines. Clearly these results indicate that there are multiple pathways that are affected
by the overexpression of this one gene. IPA also produced multiple networks of interacting
genes, many of which were differentially expressed between the two cell lines. We selected
differentially expressed genes that were found in the most highly rated IPA network, as well
as some of the other networks and are directly involved in controlling the cell cycle and
proliferation for further analysis. When we determined which PAGE pathways or gene sets
contained target genes, some appeared in the same pathways, others were found alone.
However, only two of the genes, TGFβ3 and FN1, were found in two pathways that were
differentially expressed, and the rest of the genes were found in pathways that were not
significantly different between the cell lines. Therefore, in our analysis, there does not seem
to be a relationship between the gene sets identified by PAGE and the network from IPA. This
result may be due to the different methods for choosing genes that belong to any given pathway.
The mRNA expression levels of all of the genes that we analyzed positively correlated with
the microarray data. In addition, we carried out qRT-PCR on BCL2 and BAX, and those results
also correlated with the microarray data. Our results give us confidence that the microarray
data is accurately reflecting transcriptional differences between the MCF10A/Neo and
MCF10A/Bcl-2 cell lines. However, the western blot results did not show that protein
expression correlated with mRNA expression in all cases. In addition, we were not able to
detect several proteins by western blot, although we used higher concentration of the antibody
than suggested. Tools for mRNA analysis are more robust than tools for protein analysis;
western blotting is a technique that relies on antibodies that are highly variable, and therefore
it is difficult to use as a quantitative method. However, in the following discussion we will
attempt to integrate our results to arrive at a gene and protein expression pattern that may
explain the slow-growth phenotype observed.
CDC25A
Cdc25A is a phosphatase that promotes cell cycle progression by activating G1 cyclin
dependent kinases and has been postulated to be an oncogene.28 Recently, Cdc25A has been
proposed to control the balance between proliferation and checkpoint response in the presence
of specific neu/ras oncogene activation.29 The Cdc25A phosphatase removes inhibitory
phosphates from tyrosine and threonine residues of Cdk2.28,30 This dephosphorylation is
necessary for S phase initiation.31 In a study that sampled breast carcinomas, high levels of
CDC25A mRNA were seen in 47% and were associated with poor prognosis.30 The same
study showed that CDC25A allows MCF7, a breast cancer epithelial cell line, to progress into
the S phase. In these cells that overexpress CDC25A there is also a higher level of Cdk2
enzymatic activity. It was also shown that when MCF7 cells are transfected with antisense
oligonucleotides for CDC25A to decrease CDC25A expression, there is a subsequent decrease
in Cdk2 activity. This data suggests that Cdc25A is required to maintain Cdk2 activity in MCF7
cells.
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The microarray analysis shows that in the MCF10A/Bcl-2 cell line, CDC25A is significantly
downregulated, to 30% of that present in the control (Table 1, Fig. 6). This low level of
expression may be insufficient to carry out complete dephosphorylation of Cdk2 to allow
progression to S phase. Therefore, it is possible that the low levels of CDC25A mRNA are the
primary reason for the slow growth phenotype observed in MCF10A overexpressing Bcl-2.
As to mechanism of transcriptional regulation of CDC25A, cell cycle progression occurs upon
phosphorylation of pRb, which binds to E2F when dephosphorylated and prevents E2F from
functioning as a transcription factor. E2F-regulated genes include CDC25A.32 However,
complete phosphorylation of pRb and activation of E2F requires both cyclin D-Cdk4/6 and
cyclin E-Cdk2 activities.33 Bcl-2 has been shown to directly bind Cdk2, reducing its kinase
activity which leads to hypophosphorylated pRb and inhibition of E2F.34 Therefore,
downregulation of CDC25A in MCF10A/Bcl-2 cells may be attributed to inhibition of E2F.
CDC42
As Cdc42 is slightly overexpressed at the protein level, it may have a role in the slow-growth
phenotype. Cdc42 is a member of the Rho family of small GTPases that have roles in organizing
the actin cytoskeleton and cell cycle progression.35 Cdc42 involvement in the cell cycle
includes spindle assembly and positioning, micro-tubule-kinetochore attachment, promoting
the G1/S progression in a variety of cell types, and activating a signal transduction pathway
that controls the polarity of the microtubules during mitosis.35-38 It has been hypothesized
that Cdc42 is sufficient to cause anchorage-independent cell cycle progression in mouse
embryonic fibroblasts.39 Cdc42 functions through modulation of p38 MAPK, and it was found
that in non-adherent cells, p38 activity was impaired, thus allowing cell cycle progression.39
However, Cdc42 has also been shown to inhibit cell proliferation in NIH 3T3 cells by causing
arrest in G1.40 In these cells, the expression of CDC42 increased the levels of activated p38.
p38 can cause cells to undergo cell cycle arrest, as it activates a stress pathway that inhibits
cell cycle progression. It was proposed that Cdc42 and p38 could prevent the cell from
progressing into the S phase by inhibiting G1 cyclins. We conclude that one effect of the
overexpression of BCL2 in MCF10A cells is a subsequent slight increase in Cdc42 levels that
raise active p38 levels and contribute to a slowed cell cycle progression. Such overexpression
of Cdc42 may also lead to chromosomal instability.
Cyclin D1, Fn1 and TGFβ3
CCND1 is an oncogene that is commonly overexpressed in tumors,41 however, its expression
is not associated with increased tumor proliferation.42 However, cyclin D1 has been shown to
play a role in cell migration that is required for tumor metastasis through inhibition of
expression of the ECM protein TSP-1.29,38,43 Lin et al., suggested that Bcl-2 induces
CCND1 expression by causing the activation of the promoter, through activation of focal
adhesion kinase (FAK).10 They showed that BCL2 overexpression in MCF10A cells caused
FAK to be more efficiently activated regardless of cell anchorage. These results suggest that
BCL2 caused the upregulation of CCND1 through a cell adhesion-signaling pathway.10
There a number of mechanisms as to how FAK could promote CCND1 transcription. In
NIH3T3 fibroblasts, FAK increases the transcription of CCND1 by enhancing the binding of
an Ets transcription factor to the Ets B element of the CCND1 promoter.44 CCND1
transcription is also induced by an interaction between fibronectin (Fn1) and FAK.18 That
interaction transmits a signal to Rac, inducing CCND1 transcription. Fn1 is present in the ECM,
plasma membrane, and cytoplasm and is specifically involved in stromal matrices, which are
commonly found at the site of injury and inflammation.18 Components of the ECM have a
widespread effect on proliferation and differentiation of cells in culture, and the ability of the
cells to grow independently of cell matrix interactions is a major event in malignant
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transformations.45 Although FAK was not significantly increased, the microarray data and
qRT-PCR did show an increase in FN1 expression in the MCF10A/Bcl-2 cell line, and slight
overexpression at the protein level. There was also a significant increase in the levels of
TGFβ3, which stimulates the transcription of FN1,18,46 although we were unable to detect
Tgfβ3 by western blot. Therefore, the increase in CCND1 expression could be through FAK-
Fn1 signaling through Rac.
Our results differ from Lin et al.10 in that we did not see overexpression of cyclin D1 at the
protein level. It may be that our lysate preparation for the western blot was not exactly the
same, and that under some conditions we also may see overexpression of cyclin D1.
Nevertheless, we both showed a slow cell cycle upon BCL2 overexpression in MCF10A cells.
Since other proteins change in levels of expression that could be responsible for the phenotype,
and since it has been reported that overexpression of CCND1 is does not always affect cell
proliferation in vivo,42 and in vitro,47,48 we attribute our slow cell cycle phenotype to changes
in expression of other proteins besides cyclin D1.
Our western analysis shows that Fn1 and Cdc42 are only slightly overexpressed, and cyclin
D1 is not overexpressed at the protein level. There may be a feedback mechanism at the
translational or post-translational level that results in maintaining levels of these proteins in
spite of overexpression of the mRNA. In fact, proapoptotic Bax is probably similarly regulated,
albeit in the opposite direction, as BAX is slightly downregulated at the mRNA level (Fig. 6),
but there is increased Bax protein (Fig. 7). Others have reported that overexpression of
BCL2 causes a consequential increase in Bax levels by stabilizing the Bax protein.49 Cyclin
D1 has been shown to be post-translationally regulated by both ubiquitin-dependent and -
independent degradation pathways.50 Therefore, it is possible that in our cell line, these
pathways are altered upon BCL2 overexpression to function in maintaining cyclin D1 at steady-
state levels. The same type of mechanism may be at work for other proteins such as Cdc42
also, as mRNA abundance is almost 5-fold higher in the MCF10A/Bcl-2 cell line, but protein
is only slightly overexpressed. Our inability to see large differentials in protein expression also
may be because western analysis, since it relies on detection of binding events by two
antibodies, is not as quantitative as techniques such as qRT-PCR. Finally, as most of our
proteins are involved in the cell cycle, it may be that steady state levels are only slightly
changed, but the kinetics of expression are altered, which we would only detect by western
analysis of lysates taken from a time-course of synchronized cells.
Besides an inhibition of E2F-mediated gene transcription, there are several possible
mechanisms whereby Bcl-2 affects transcription. Bcl-2 has been shown to regulate NFAT-
transcription factor in T cells and this effect is Ca2+-mediated.51 Bcl-2 is known to affect
Ca2+ homeostasis in the ER and mitochondria.52,53 Ca2+ is a known modulator of
transcription, as it has been shown to regulate c-Src through binding to calreticulin which
affects FN1 transcription.54 In addition, Bcl-2 blocks p53-dependent apoptosis, specifically
the transcriptional repression function of p53, while leaving the transcriptional activation
function of p53 intact.55,56 This effect may be due to binding by Bcl-2 to the transcriptional
repressor Btf.57 Similarly, Bcl-2 modifies the transcriptional repressor function of the
glucocorticoid receptor, which directly binds the transcriptional activator AP-1 to block its
effects.58 Therefore, Bcl-2 allows the glucocorticoid receptor to remain active as a
transcriptional activator. Bcl-2 has been shown to downregulate the transcriptional activity of
NFκB, a transcription factor involved in cell death.59 A proapoptotic Bcl-2 family member,
Bad, has been shown to interact with c-Jun to inhibit transcription of cyclin D1 in breast cancer
cells.60 Finally, a viral Bcl-2 homolog, adenovirus E1B 19-kDa protein, has demonstrated
similar transcriptional activities.56 In addition, E1B has been shown to act as an enhancer-
dependent transcriptional activator for various promoters,61 and specifically activates c-Jun
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mediated transcription.62 A similar role for Bcl-2 could potentially cause large numbers of
genes to be upregulated, as we see occurring in our MCF10A/Bcl-2 cell line.
In summary, the overexpression of BCL2 in MCF10A cells showed a large effects on a number
of genes that are involved in the cell cycle. We expected BCL2 to downregulate genes that
were involved in cell cycle progression and this was observed with CDC25A. However, this
effect was not observed with CCND1, which normally is associated with increased cell cycle
progression, but the level of cyclin D1 protein was maintained. Although CDC42 can stimulate
the cell cycle, its overexpression is also associated with G1 arrest, which supports the slow-
growth phenotype observed. Finally, the reduction of CDC25A expression alone may be
sufficient to slow the cell cycle. Our results give a slight cautionary note to interpretation of
microarray and qRT-PCR results, as several genes that were found to be overexpressed by
these methods show compensatory changes that result in reduced levels of protein. In addition,
several of our antibodies did not detect any protein, although the mRNA is present in the cell.
Western analysis may not be sensitive enough for some proteins to detect changes at the mRNA
level. In a similar study of overexpression of oncogenes in breast epithelial cells, some protein
markers were not readily detected by western analysis.63
Materials and Methods
Cell culture
MCF10A cells were obtained from the Karmanos Cancer Institute (Detroit, MI). For routine
culturing, the cells were maintained as subconfluent monolayers at 37°C and 5% CO2 in
Dulbecco’s modified Eagle’s medium/Ham’s F-12 nutrient mixture (DMEM/F-12), containing
15 mM HEPES and 2.5 mM L-glutamine, supplemented with 5% heat inactivated equine
serum, 500 ng/ml hydrocortisone, 21.5 ng/ml epidermal growth factor (EGF), 10 μg/ml insulin,
100 ng/ml cholera toxin, and 10 μg/ml gentamicin (hereafter referred to as DMEM/F-12
complete). MCF10A/Bcl-2 and MCF10A/Neo were grown under the same conditions.
Reagents
DMEM/F-12, L-glutamine, and HEPES were obtained from MediaTech. Epidermal growth
factor, hydrocortisone, insulin, and staurosporine were acquired from Sigma. Equine serum
was obtained from Bio-Witaker. Gentamicin was obtained from Invitrogen. All other reagents
were from Fisher Scientific unless otherwise noted.
Construction of cell lines
An MCF10A cell line that stably overexpresses BCL2 and an MCF10A vector control cell line
were produced by infection of MCF10A cells with a retroviral vector containing either murine
BCL2 under control of the SV40 promoter and neomycin resistance (neor) genes (PA317/
Bcl-2) or neor (pZip/Neo) alone as described.66 Briefly, MCF10A cells were infected with 1
× 106 PA317/Bcl-2 virus particles or 1 × 105 pZip/Neo virus particles in the presence of 10
μg/ml of polybrene (Sigma) for 4 h. Cells stably expressing BCL2 and the neomycin resistance
marker (MCF10A/Bcl-2) or the neomycin resistance marker alone (MCF10A/Neo) were
selected by growth in DMEM/F-12 medium supplemented with 2 mg/ml of the neomycin
analog G418 (Invitrogen). Several neomycin resistant clones from each infection were pooled,
thus minimizing artifacts from gene insertion into a specific site.
Proliferation assay
Cells were seeded at a concentration of 100,000 cells per 35 mm dish in complete medium.
Cell counts were determined every 24 h for 10 days. Viable cells were counted by trypan blue
exclusion as follows. Cells were harvested by trypsinization in 0.1% trypsin/1.06 mM EDTA
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in Hanks Balanced Salt Solution (Invitrogen) and collected by centrifugation. The cells were
resuspended in 1 ml PBS. 200 μl of cell suspension was added to 600 μl of PBS and 200 μl of
a 0.4% trypan blue stain (GIBCO). Ten μl of cell suspension was added to each side of a Bright-
line hemocytometer. The cells were counted under 400x magnification. The results were
graphed with Microsoft Excel, and unpaired t-tests were used to determine significant
differences (p < 0.025).
Cell synchronization and flow cytometry
Synchronization via growth factor withdrawal—Subconfluent monolayers in 75 cm2
flasks were washed twice with 10 ml of PBS containing 1 mM EDTA. Pre-warmed growth
factor (GF) withdrawal media (DMEM/F-12 with 15 mM HEPES, 2.5 mM L-glutamine and
10 μg/ml gentamicin) (10 ml) was then added to each flask. After 5 days of GF withdrawal,
media was removed and complete media was added. Cells were harvested by trypsinization at
0, 12, 15, 18, 21, 24, 30 and 36 h after complete media addition. Cells were then prepared for
flow cytometric analysis.
Synchronization via colchicine—Cells were washed twice with 10 ml of PBS, then 10
ml of complete media with 0.1 μM colchicine (Sigma) was placed on the cells (time 0), and
cells were harvested by trypsinization at 1, 2, 3, 4 and 5 days. Cells were then prepared for
flow cytometric analysis.
At each time point, the cells were centrifuged at 200 × g for 5 min and the supernatant was
removed. The cells were washed once with PBS, and resuspended in 1 ml of complete media.
The cells were fixed by passage through a 23 g needle into cold 70% ethanol. The cells were
stored at −20°C until all samples were collected. The cells were centrifuged and then washed
in 1 ml PBS. RNase (10 μl of 1 mg/ml) was added and incubated at 37°C for 30 min then
washed with PBS. Cells were then resuspended in 1 ml PBS and 10 μl of a 1 mg/ml propidium
iodide (PI), incubated in the dark for 30 min at RT, then placed on ice and analyzed on a
FACScan flow cytometer (Beckton Dickinson). Ten thousand events were captured and the
analysis was performed on Modfit v. 3.1. Unpaired t-tests were carried out to determine
significant differences between the two cell lines at each time point (p < 0.05).
Microarray analysis
RNA was prepared using the Totally RNA™ Kit (Ambion). Samples were treated for possible
DNA contamination with the Turbo DNA-free kit from Ambion. The purity and quantity of
the RNA was determined by measuring the A260/A280 ratio on a BioPhotometer (Eppendorf).
The human cDNA array consisted of full-length cDNA clones generated by the National
Cancer Institute’s Mammalian Gene Collection. The cDNA arrays developed from these clones
consist of 9600 features, with 1152 blank spots. Each membrane contained 384 sub arrays with
24 genes on each sub array. Each spot represented an individual gene, thus the array
incorporated over 9000 unique genes. Total RNA was radioactively labeled with [α 33P] dCTP.
Details of the labeling and array protocols have been described.67 Briefly, total RNA (20 μg)
was reverse-transcribed to cDNA with reverse-transcriptase enzyme in the presence of [α 33P]
dCTP. The [α 33P] dCTP-cDNA was purified through a spin column by size separation
(BioSpin, Bio-Rad) from [α 33P] dCTP and the heat denatured probe (5 × 106 cpm) was diluted
in 4 ml of Microhyb solution (RG) and hybridized to the array for 16–18 h at 50°C with rotation.
The target cDNA was spotted on the nylon membranes and hybridized overnight at 50°C with
labeled probe cDNA from each cell line. cDNA from each cell line was arrayed in triplicate.
Hybridized arrays were rinsed in 2 X SSC and 0.1% SDS twice at 55°C. The microarrays were
exposed to phosphor screens for 1–3 days, and then scanned with the Phosphorimager 860 at
50 μm pixel resolution. ArrayPro software was used to convert the hybridization signals into
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raw intensity values, which was then transferred to a Microsoft Excel spreadsheet for further
analysis.
Array data analysis and analysis tools
In order to compare the array data between the two cell lines, the raw intensities values were
normalized using Z transformation.22 The following equation was used to calculate Z scores
of each raw value:
where G1 represents any gene on the microarray and G1…Gn represents the measure of all the
genes on the microarray. The natural logarithm was used to decrease the variance and put the
data on small scale. Genes whose average intensity between the two treatments was greater
than zero were eliminated from further calculations. In addition, genes of low intensity
compared to background, showing a high fold change, were also eliminated.23 Gene
expression differences between the two arrays were calculated using the following equations:
where G1, Neo represents the Z score for a gene in the MCF10A/Neo cell line and G1, Bcl-2
represents the Z score for the same gene in the MCF10A/Bcl-2 cell line. The Z ratios were
used as a measure of fold-change between the two cell lines. p values were calculated from the
filtered genes, using t-tests, to test for repeatability among the replicate arrays. Only the genes
having a p-value <0.05 are and having a Z ratio >1.5 were used in further analysis. The standard
deviation of the Z difference of all the genes on the array was used to determine whether a
given ratio was statistically significant considering the array as a whole. Parametric analysis
of gene set enrichment (PAGE) a module of DIANE software, a microarray analysis platform,
was used to identify groups of genes that were significantly enhanced.24,25 Ingenuity Pathway
Analysis (IPA) was used to determine the biological pathways in which the genes that were
over or under expressed significantly were involved.26
Quantitative reverse transcription PCR
Vector NTI (Invitrogen) was used to display the mRNA sequence of target genes (Table 2). A
300 bp sequence that crosses an intron-extron junction was selected and subjected to BLAST
analysis to ensure there was no homology with other genes.68 The sequence was pasted into
Mfold to determine how the mRNA would fold at the specific annealing temperature.69,70
The annealing temperature that was used for all of the primers was 55°C. Primer3 was used to
select the appropriate forward and reverse primers that would avoid the secondary structure of
the RNA and minimize the formation oligo-duplexes.71 The primers were all 19–23 bp in
length and produced amplicons of 72–150 bp (Table 2).
cDNA for qRT-PCR was prepared with the RETROscript kit from Ambion. Reverse
transcription was performed using 1 μg of total RNA. To confirm the microarray results,
quantitative RT-PCR (qRT-PCR) was performed from cDNA. GAPDH served as the control
in each qRT-PCR reaction. The reactions were carried out on an Icycler IQ (BioRad). Each 25
μl PCR reaction included SYBR Green Supermix (Bio Rad), containing 0.4 mM each of dATP,
dCTP, dGTP and dTTP, 50 U/ml iTaq DNA polymerase, 6 mM Mg2+, SYBR Green I, 20 nM
fluoroscein, and stabilizers. The reaction also contained cDNA from one cell line and the
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forward and reverse primers specific for the gene of interest. The efficiency of each primer set
was calculated using a standard curve. Dilutions of cDNA ranging from 0.37–30 ng were
prepared and the cycle threshold (Ct) values for the reactions were plotted against the cDNA
concentrations. The slope of the line was used in the following equation: E = 10(−1/slope) to
calculate the efficiencies. All efficiencies were greater than 90%. We used the comparative
cycle threshold method (2−ΔΔCt) to quantify gene expression.72 Each PCR reaction was carried
out on at least two separate cDNA preparations. Fold-change values represent an average of
the two separate experiments. Each reaction was normalized to the housekeeping gene
(GAPDH) with the following equation:
Western blotting
Cells were lysed by vortexing on ice in 50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA,
1% Triton X-100, 1 mM PMSF, 1% protease inhibitor cocktail (Sigma). Protein concentrations
were determined by the Bradford method (BioRad).73 Discontinuous SDS-PAGE was carried
out using the X-Cell SureLock system (Invitrogen). Total cellular protein (50 μg) was separated
on SDS-polyacrylamide gels, then transferred to Immobilon-Psq polyvinylidene difluoride
(PVDF) membranes (Millipore). For immunodetection the membranes were incubated in
blocking buffer (5% non-fat dry milk dissolved in Tris-buffered saline solution with 0.05%
Tween-20 (TBS-T)) for 60 min at RT to block all non-specific binding sites. The membranes
were then incubated with the primary antibody diluted in blocking buffer for 60 min at RT.
After the primary antibody incubation the membranes were washed in TBS-T. The membranes
were then incubated with the horseradish peroxidase conjugated secondary antibody for 60
min at RT, then washed in TBS-T. Proteins were visualized by enhanced chemiluminescence
plus (ECL+) system (Amersham) on a FluorChem 8900 imaging system (Alpha Innotech).
Antibodies were obtained from Santa Cruz Biotechnology, Inc., (Santa Cruz, CA) or
Developmental Studies Hybridoma Bank (University of Iowa, Iowa City).
Conclusion
Multiple pathways are affected by BCL2 overexpression in breast epithelial cells, and more
than one gene is likely responsible for the slow-growth phenotype observed. However,
although we saw excellent correlation between the microarray and qRT-PCR results, the
protein expression data did not always correlate. This finding may implicate translational and
post-translational regulation mechanisms in maintaining steady-state protein levels.
It appears that BCL2 has evolved the ability to block apoptosis along with slowing the cell
cycle, thus working in conjunction with other oncogenes to promote tumorigenesis.6,64
BCL2’s multiple functions in its role as a proto-oncogene is not surprising, given the fact that
many proteins that have one function may be co-opted for other functions that promote cancer.
64,65 As a mitochondrial protein, it has been suggested that Bcl-2 may act in conflict with the
nuclear genome (intragenomically) in promoting cancer at the expense of the organism.65
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Figure 1.
Western blot analysis of MCF10A (M), MCF10A/Neo (N) and MCF10A/Bcl-2 (B), with an
antibody to Bcl-2. Lysates were prepared from exponentially proliferating cells. Protein (30
μg) was loaded onto a 12% SDS PAGE gel and subjected to immunoblot analysis. β actin
antibody was used as a loading control.
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Figure 2.
Graph depicting the growth curves for MCF10A, MCF10A/Neo, and MCF10A/Bcl-2. Each
cell line was plated at 100,000 cells per 35 mm dish and counted by trypan blue exclusion every
day for 10 days. Points represent means, error bars represent standard error of three independent
experiments.
Long et al. Page 18
Cell Cycle. Author manuscript; available in PMC 2009 February 2.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 3.
Analysis of the cell cycle of MCF10A/Neo (A) and MCF10A/Bcl-2 cells (B) by growth factor
withdrawal (GF) and MCF10A/Neo (C) and MCF10A/Bcl-2 (D) cells by colchicine treatment.
For (A and B), cells were incubated without GF for five days and then GF were added, and
cells were grown for an additional 60 h. For (C and D), cells were treated with 100 nM
colchicine for five days. At each time point, cells were fixed in ethanol and stored at −20°, then
were treated with RNAse, stained with PI, and analyzed by flow cytometry with ModFit
software. Bars represent means, error bars represent the standard error of three independent
experiments carried out in duplicate.
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Figure 4.
(A) PAGE bar graph representing pathways significantly different between MCF10A/Neo
(green) and MCF10A/Bcl-2 (gold) cell lines and the pathway corresponding Z score. (B) Bar
graph representing ten gene sets identified by PAGE that contained one or more target genes.
Three of the gene sets shown were identified as being significantly different between the two
cell lines: Frasor ER Down, Bcl-2 Family and Regulatory Network, and Hemo TF List JP.
These pathways are named according to their gene complement.25 See text for details.
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Figure 5.
(A) Ingenuity pathway analysis (IPA) network representation of the most highly rated network.
The genes that are shaded were determined to be significant from the statistical analysis. The
intensity of the shading shows to what degree each gene was up or downregulated. The Z ratio
is also displayed under each shaded gene. The genes shaded red are upregulated and those that
are green are downregulated. A solid line represents a direct interaction between the two gene
products and a dotted line means there is an indirect interaction. (B) Network showing only
the interactions of the nine target genes.
Long et al. Page 21
Cell Cycle. Author manuscript; available in PMC 2009 February 2.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 6.
Comparison of the fold change values (ΔΔ Ct) obtained from qRTPCR analysis for each gene
in the network shown in Figure 5B, plus Bax. Genes that were upregulated according to the
microarray analysis (blue) showed a significant increase in expression and genes that were
down-regulated according to the microarray showed a significant decrease in expression (grey).
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Figure 7.
Western blot of MCF10A/Neo (N) and MCF10A/Bcl-2 (B) cell lines. Protein (50 μg) was
subjected to SDS-PAGE followed by immuno-blotting analysis with corresponding antibodies.
GAPDH was used as a loading control.
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Table 2
Genes amplified by qRT-PCR and their primers
Gene symbol GenBank accession number Amplicon Primer sequence
BCL2 NM_000633 127 bp For 5′-CCTGTGGATGACTGAGTACC-3′Rev 5′-GAGACAGCCAGGAGAAATCA-3′
BAX NM_138761 115 bp For 5′-TTTGCTTCAGGGTTTCATC-3′Rev 5′-CGTCCCAAAGTAGGAGAGGA-3′
CDC25A NM_001789 150 bp For 5′-GCCTGTCACCAACCTGAC-3′Rev 5′-CCAGGAGAATCTAGACAGAAACC-3′
CDC42 NM_001791 116 bp For 5′-GCTGTCAAGTATGTGGAGTG-3′Rev 5′-ACACACCTGCGGCTCTTCTT-3′
CCND1 NM_053056 75 bp For 5′- GCTCCTGGTGAACAAGCTCAA-3′Rev 5′-TTGGAGAGGAAGTGTTCAATGAA-3′
CYR61 NM_001554 100 bp For 5′-ACTTCATGGTCCCAGTGCTC-3′Rev 5′-AAATCCGGGTTTCTTTCACA-3′
AKR1C3 NM_003739 85 bp For 5′-GTAAGGATGCAGGATTGG-3′Rev 5′-AGTCCTGGCTTGTTGAGG-3′
FN1 NM_212482 92 bp For 5′-TGTCTTGGTAATGGAAAAGG-3′Rev 5′-TCTCCGACCACATAGGAAG-3′
MMP1 NM_002421 72 bp For 5′-GGGAGATCATCGGGACAACTC-3′Rev 5′-GGGCCTGGTTGAAAAGCAT-3′
TGFβ3 NM_003239 82 bp For 5′-ATGGAAATCAAATTCAAAGG-3′Rev 5′-ATTAGATGAGGGTTGTGGTG-3′
TGFβI NM_000358 115 bp For 5′-GCTGTCCTGGATATGAAAAG-3′Rev 5′-GTGTACAGCTGAGTGGTGGT-3′
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